Pharmaceutical company Orano Med has commenced construction of its manufacturing facility, Alpha Therapy Laboratory (ATLab) Valenciennes, in Onnaing, France.
The lab is said to become Europe’s first industrial-scale facility dedicated to the production of lead-212-based radioligand therapies.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Once built, the facility will help address the production challenges of these therapies and meet the needs of cancer patients with limited treatment options.
The ground-breaking ceremony for the facility was attended by Onnaing mayor Xavier Jouanin; Valenciennes Métropole president and Valenciennes mayor Laurent Degallaix; as well as regional councillor for the Circular Economy Aurore Colson, among others.
Targeted Alpha Therapy uses lead-212 to combine biological molecules’ targeting capabilities with the cell-killing properties of alpha emissions.
The facility, spanning more than 3,000m², represents an investment of €29m ($31.24m).
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataOrano Projects & Innovation R&D and Nuclear Medicine senior executive vice-president Guillaume Dureau said: “The ATLab in Onnaing is a very important step in our development strategy and is situated at the very heart of the industrial fabric of the Valenciennes metropolitan area and the Hauts-de-France region.
“The expansion of our production capacity in the radiopharmaceutical field is part of a drive to revitalise our country’s industrial and economic fabric.”
The development is expected to create 25 direct jobs and will concentrate on producing and distributing lead-212 therapies developed by Orano within Europe.
It has also been selected under the France 2030 plan and will receive public funding of approximately €3.8m to work towards this.
